Serum adiponectin level in obese and non-obese COPD patients during acute exacerbation and stable conditions

Abstract

AimTo assess serum adiponectin in obese & non obese COPD during exacerbation and stable conditions and its relation to ventilatory functions. Subjects and methodsThe study was conducted on 40 male COPD patients during exacerbation and stable conditions with 15 age matched healthy control subjects. Patients and control were divided into non-obese and obese according to their body mass index. Subjects were submitted to full history taking, Complete physical examination, plain chest X-ray, Complete blood count, Erythrocyte sedimentation rate, Liver and kidney functions, Fasting and post prandial blood sugar, Ventilatory functions, and Venous blood samples for Adiponectin measurement. ResultsThere was Significant difference in serum adiponectin between exacerbated nonobese COPD and nonobese controls (P<0.005) and significant difference in serum adiponectin between exacerbated obese COPD patients and obese controls (P<0.05). Significant difference was observed in serum adiponectin between nonobese stable COPD and nonobese controls (P<0.005). Significant difference was observed in serum adiponectin between exacerbated nonobese COPD and stable nonobese COPD (P<0.05). Significant difference was observed in serum adiponectin between nonobese COPD and obese COPD patients during exacerbation and stable states (P<0.001). Non significant correlation was found between changes in serum adiponectin in nonobese COPD and obese COPD (exacerbation and stable conditions) and following ventilatory functions, FVC (% pred), FEV1 (% pred), FEV1/FVC and FEF25-75 (% pred). ConclusionSerum adiponectin was significantly higher in obese and nonobese COPD than controls, the rising is more during exacerbation than stable condition and more in non obese than obese COPD and non significant correlation between changes in adiponectin and ventilatory functions was found.